Phase 3
N=89
Implantable Cardioverter-Defibrillator Use in the VA System
Cardiomyopathies
Bottom Line
View on ClinicalTrials.gov: NCT01217827 ↗Enrolled (actual)
89
Serious AEs
5.6%
Results posted
Dec 2016
Primary outcome: Primary: Referral for Implantable Cardioverter Defibrillator — 11; 1 participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- Clinical Reminder (Behavioral)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Stanford University
- Primary completion
- Jan 2011
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Referral for Implantable Cardioverter Defibrillator |
11; 1 | — |
Summary
Despite being a proven life-saving intervention in appropriately selected individuals, multiple studies continue to demonstrate low implantation of defibrillators in potential candidates. Based upon prior research, a major barrier to low utilization is low referral of potential candidates by healthcare providers. In this study, via brief clinical reminder placed in the electronic medical record, we ask healthcare providers who have not referred potential candidates for defibrillator the reasons for this decision and provide them with the tools for referral if appropriate.
Eligibility Criteria
Inclusion Criteria:Meeting published criteria for receipt of an implantable cardioverter defibrillator Exclusion Criteria:provider is not affiliated with the VA health care system
Data sourced from ClinicalTrials.gov (NCT01217827). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.